Search by Drug Name or NDC
NDC 71335-1077-04 Acyclovir 400 mg/1 Details
Acyclovir 400 mg/1
Acyclovir is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Bryant Ranch Prepack. The primary component is ACYCLOVIR.
MedlinePlus Drug Summary
Acyclovir is used to decrease pain and speed the healing of sores or blisters in people who have varicella (chickenpox), herpes zoster (shingles; a rash that can occur in people who have had chickenpox in the past), and first-time or repeat outbreaks of genital herpes (a herpes virus infection that causes sores to form around the genitals and rectum from time to time). Acyclovir is also sometimes used to prevent outbreaks of genital herpes in people who are infected with the virus. Acyclovir is in a class of antiviral medications called synthetic nucleoside analogues. It works by stopping the spread of the herpes virus in the body. Acyclovir will not cure genital herpes and may not stop the spread of genital herpes to other people.
Related Packages: 71335-1077-04Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Acyclovir
Product Information
| NDC | 71335-1077 |
|---|---|
| Product ID | 71335-1077_1e1ab04a-ed67-4b12-a671-92b86ac9153e |
| Associated GPIs | |
| GCN Sequence Number | n/a |
| GCN Sequence Number Description | n/a |
| HIC3 | n/a |
| HIC3 Description | n/a |
| GCN | n/a |
| HICL Sequence Number | n/a |
| HICL Sequence Number Description | n/a |
| Brand/Generic | n/a |
| Proprietary Name | Acyclovir |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Acyclovir |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET |
| Route | ORAL |
| Active Ingredient Strength | 400 |
| Active Ingredient Units | mg/1 |
| Substance Name | ACYCLOVIR |
| Labeler Name | Bryant Ranch Prepack |
| Pharmaceutical Class | DNA Polymerase Inhibitors [MoA], Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC], Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC], Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC], Nucleoside Analog [ |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA210401 |
| Listing Certified Through | 2023-12-31 |
Package
NDC 71335-1077-04 (71335107704)
| NDC Package Code | 71335-1077-4 |
|---|---|
| Billing NDC | 71335107704 |
| Package | 50 TABLET in 1 BOTTLE (71335-1077-4) |
| Marketing Start Date | 2022-02-14 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |